GeneThera, Inc.

Equities

GTHR

US37185E3062

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 01:14:13 2024-02-20 pm EST			5-day change	1st Jan Change
0.000001 ^USD	-99.98%		-.--%	-.--%

2022	GeneThera, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	CI
2022	GeneThera, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	CI

GeneThera, Inc. announced a financing transaction

May 17, 2021

GeneThera, Inc. (OTCPK:GTHR) announced a private placement of non-convertible debt for gross proceeds of $15,000,000 on May 18, 2021. The securities will be issued pursuant to regulation D. The minimum investment accepted from any outside investor is $10,000.

Latest news about GeneThera, Inc.

GeneThera, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
GeneThera, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-18	CI
GeneThera, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-18	CI
GeneThera, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-14	CI
GeneThera, Inc. Auditor Raises 'Going Concern' Doubt	22-04-13	CI
GeneThera, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-15	CI
GeneThera Inc. Enters into an exclusive real estate agreement with Cushman & Wakefield related to the ZIDAS project	21-10-12	CI
Genethera, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-16	CI
GeneThera, Inc. announced a financing transaction	21-05-17	CI
Genethera, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-12	CI
GeneThera Enters into Collaboration Agreement with Cumming Corporation to Build Network of Zoonotic Diseases Laboratory Facilities	21-04-27	CI
Genethera, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	21-04-14	CI
Genethera, Inc. Announces Platform for Wastewater Testing	21-04-06	CI
Genethera, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-16	CI
Genethera, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-14	CI
Genethera, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-06-24	CI
Genethera, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019	20-06-10	CI
GeneThera, Inc. Announces Resignation of Fred Oeschger from the Board of Directors	18-12-13	CI
GeneThera, Inc. Announces Directorate Changes	18-08-31	CI
GeneThera Inc. Secures New Laboratory Facilities to Expand Technology Platforms	16-01-25	CI
GeneThera Inc. Announces Board Appointments	15-04-21	CI
GeneThera, Inc. Auditor Raises 'Going Concern' Doubt	15-04-13	CI
GeneThera Inc. Enters into Exclusive Collaboration Agreement with Hudson Robotics Inc	15-03-04	CI
GeneThera Inc. Auditor Raises 'Going Concern' Doubt	14-04-15	CI
GeneThera Inc. will Change its Ticker to GTHR from GTHR.E	13-12-17	CI

Chart GeneThera, Inc.

Duration

Period

More charts

Company Profile

GeneThera, Inc. is a biotechnology company. The Company is focused on developing genetics-based diagnostic assays and vaccine solutions and molecular diagnostic tests, therapeutics, and vaccines through its technologies for controlling the spread of zoonotic infection. The Company has developed a Molecular Robotic/AI Laboratory Platform (MORAP), which combine the use of advanced robotic laboratory systems integrated with artificial intelligence software systems. Its MORAPAT is designed to prevent the spread of disease from animals and control zoonotic infectious agents. The Company has also developed a large-scale process for highly purified and high viral titer (viral concentration) Adenovirus and Adeno-associated virus (AAV) genetically engineered viruses. This technology develops Adenovirus and AAV-based recombinant DNA vaccines for zoonotic pathogens. PURIVAX is a purification system that enhances biological purity and viral titer of recombinant Adenovirus and AAV vectors.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
GENETHERA, INC.	-.--%	35
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research